MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Prostate
ImmunityBio, Inc. (NASDAQ: IBRX), formerly, NantCell*
Organization & Developments: ImmunityBio
Parents
ImmunityBio, Inc. (NASDAQ: IBRX), formerly, NantCell*
Children
*A clinical-stage immunotherapy company
*ImmunityBio is a leading, late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases
*The company’s immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term “immunological memory.”
*Vertically integrated company that has established GMP manufacturing capacity at scale with cutting-edge cell manufacturing expertise and ready-to-scale facilities, as well as extensive and seasoned R&D, clinical trial, and regulatory operations and development teams.
2021: ImmunityBio + NantKwest _ 39th Annual JP Morgan Healthcare Conference
2021: ImmunityBio targets cancer and COVID-19
2021: Soon-Shiong pledges $210 million for South African vaccine development
2021: WRAIR_ImmunityBio Announces Launch of Phase 2 Trial of IL-15 Superagonist Anktiva with Antiretroviral Therapy to Inhibit HIV Reservoirs
2022: Arbitrator awards $157M to Soon-Shiong's ImmunityBio in dispute with Sorrento
2022: Dunkirk retreat: ImmunityBio, aiming to hire 300 in 30 months, lays off staff at new facility
2022: ImmunityBio Announces $157 Million Financing From Nant and Institutional Investor
2022: ImmunityBio_Overview Presentation
2022: ImmunityBio: Demoralization Of The Bulls By Deflating The Share Price
2022: ImmunityBio: PDUFA Pending_ seekingalpha.com
2022: ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission_ seekingalpha.com
2022: More Capital Needed ImmunityBio Loses $166M In Second Quarter
2023: After FDA rejection, ImmunityBio lays off staff in California and Florida
2023: FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
2023: ImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ
2023: ImmunityBio Isn't Assured Of Bringing Relief For Bladder Cancer_seekingalpha.com
2023: ImmunityBio: _Ongoing Dilution & Regulatory Uncertainties Blur Investment Prospects
2023: ImmunityBio: Anktiva Rejection Heightens Financial Urgency_ seekingalpha.com
2023: ImmunityBio: Approval Likely Priced In, Yielding Mostly Risk For Would-Be Buyers_ seekingalpha
2023: ImmunityBio: Huge Slump On Small Raise Before Approval Raises Questions_seekingalpha.com
2023: ImmunityBio: The CRL Makes It Riskier Than Ever (NASDAQ:IBRX)
2023: ImmunityBio: Upcoming PDUFA, Solid Data, Confusing Finances_ seekingalpha.com
2023: Soon-Shiong is set back again
2024: 800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
2024: ImmunityBio Completes ANKTIVA’s Post-Approval Enrollment of the 100th Patient in BCG Unresponsive NMIBC CIS Trial and Reports a Complete Response Rate of 71% with a Durable Duration of Response Ranging Up to 54 Months
2024: Immunitybio Inc. (IBRX): Among the Most Promising Cancer Stocks According to Hedge Funds
2024: ImmunityBio inoculates itself against financial pain, inking $210M royalty deal to get cancer drug to market
2024: ImmunityBio Presents Positive Long-Term Overall Survival Data in Non-Small Cell Lung Cancer Patients and Announces Registrational Intent Phase 3 Trials with ANKTIVA® and Checkpoint Immunotherapy at World Conference on Lung Cancer
2024: ImmunityBio, Inc. Announces Pricing of Public Offering of Common Stock
2024: ImmunityBio: All Eyes On Execution Now (Rating Upgrade)
2024: ImmunityBio: Anktiva Approval Opens Up A World Of Possibilities, Risks And Potential Gains
2024: ImmunityBio: Anktiva Launch, Good Data, Low Cash, High Debt
2024: ImmunityBio: Anktiva's Launch Progresses - Bladder Cancer Drug May Be 'Real Deal'
2024: ImmunityBio: Buy Low Now Vs. Buy High Later
2024: ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025
2024: ImmunityBio: Continued Volatility Suggests Further Upside Potential, But I'd Be Careful
2024: ImmunityBio: Despite Share Price & Funding Woes, Muddy Path To Long-Term Success
2024: ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise
2024: ImmunityBio: Forging A New Plan After Recent $100 Million Offering
2024: ImmunityBio: Moving The Needle_seekingalpha.com
2024: ImmunityBio's Anktiva: Promising, But Organizational Complexity Keeps Me Cautious
2024: ImmunityBio's Cash Burn And Dilution Dampen Anktiva's Potential
2024: ImmunityBio’s ANKTIVA® Now Covered By More Than a Dozen Insurance Plans Representing Over 100 Million Lives Within Months of FDA Approval
2024: Patrick Soon-Shiong's ImmunityBio bags FDA approval for Anktiva to challenge Merck in bladder cancer
2025: As J&J aims to 'fundamentally change' how bladder cancer type is treated, ImmunityBio plays defense
2025: Assessing ImmunityBio After Recent Cancer Immunotherapy Headlines and Ongoing Stock Volatility
2025: ImmunityBio announces collaboration with Beigene_seekingalpha.com
2025: ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
2025: ImmunityBio Announces Permanent J-code (J9028) for ANKTIVA® Is Now Effective
2025: ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
2025: ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025
2025: ImmunityBio stock gains 15% amid regulatory updates
2025: ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
2025: ImmunityBio, Inc. (IBRX) Targets Lymphopenia with Cancer BioShield™ Platform
2025: ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
2025: ImmunityBio: Despite Anktiva's Clinical Promise, This Remains A Difficult Investment_seekingalpha.com
2025: ImmunityBio: Lymphopenia Opportunity Could Provoke Short Squeeze
2025: ImmunityBio: Making Its Next Strikes After Bladder Cancer Approval
2025: Piercing the hype around Patrick Soon-Shiong's 'Bioshield' cancer treatment
2025: UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
2026: ImmunityBio (IBRX): One of the Best Performing Growth Stocks So Far in 2026
2026: ImmunityBio touts 15-month complete response in off-the-shelf CAR-NK tria
2026: ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM
2026: ImmunityBio: None Of The Moonshots Is Priced In
2026: ImmunityBio: One Approval Away From A Multi-Billion Dollar Breakout (NASDAQ:IBRX)
2026: ImmunityBio: Why I Am Upgrading To A Buy For 2026 (NASDAQ:IBRX)
Jumps
Finance & Acquisitions: ImmunityBio
Key People: ImmunityBio